FindMyKOL
Clinical trialNCT04879121RecruitingPhase 2Interventional

Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors

NCT04879121 is a phase 2 interventional trial sponsored by M.D. Anderson Cancer Center. As of 21 Nov 2026, it is recruiting participants. It studies Larotrectinib in Locally Advanced Malignant Solid Neoplasm and Metastatic Malignant Solid Neoplasm. The registry lists an enrollment of 13 participants at 1 site in 1 country. The registry lists a start date of 30 Apr 2021 and a primary completion date of 11 Nov 2027. One of its registered investigators has a FindMyKOL profile.

SponsorM.D. Anderson Cancer CenterEnrollment13Locally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT04879121
FieldValue
Registry IDNCT04879121
StatusRecruiting
PhasePhase 2
Study typeInterventional trial
Lead sponsorM.D. Anderson Cancer Center
Enrollment13
Registered sites1
Countries1
ConditionsLocally Advanced Malignant Solid Neoplasm and Metastatic Malignant Solid Neoplasm
DrugsLarotrectinib
Start30 Apr 2021
Primary completion11 Nov 2027
Study completion11 Nov 2027
Last update posted7 Oct 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II trial studies the effect of larotrectinib in treating patients with NTRK gene amplification positive solid tumors that have spread to nearby tissues or lymph nodes (locally advanced) or other places in the body (metastatic). Larotrectinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Texas, United States1 site, 1 recruiting
  • M D Anderson Cancer Center

    Houston

    David S. Hong
    Recruiting

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexas: 1 site, 1 recruitingTX1FloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT04879121

Each answer restates registry values shown on this page.

What is NCT04879121?

NCT04879121 is a phase 2 interventional trial sponsored by M.D. Anderson Cancer Center. It studies Larotrectinib in Locally Advanced Malignant Solid Neoplasm and Metastatic Malignant Solid Neoplasm.

Is NCT04879121 recruiting?

As of 21 Nov 2026, it is recruiting participants. 1 of its 1 sites list their own status as recruiting.

Who leads NCT04879121?

The registry names David S Hong (principal investigator, M.D. Anderson Cancer Center) as the overall official.

Where does NCT04879121 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT04879121 study?

The registered drug and biological interventions are Larotrectinib.

When is NCT04879121 expected to complete?

The registry lists a primary completion date of 11 Nov 2027 and a study completion date of 11 Nov 2027. The sponsor last updated the record on 7 Oct 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.